Rapid Image-Based Screening for Bioactive Compounds that Block SARS-CoV-2 Replication Cycle

Case ID:

This invention is a rapid image-based drug screening software platform for bioactive compounds that can block SARS-CoV-2 replication cycles. The invention utilizes a custom image processing algorithm that utilizes microscopy images to develop drug response profiles to identify lead compounds. This technology can also be used to neutralize antibodies, monobodies, or peptides.

Within the drug discovery process, lead compounds are chemical compounds that show desired biological or pharmacological activity and may initiate the development of a new clinically relevant compound. Lead compounds are commonly used as a starting point in drug design. With the advancement of technology, computer-aided drug design (CADD) has been incorporated into lead compound discovery within the drug discovery process.  

Since the severe acute respiratory syndrome SARS-CoV-2 (Coronavirus) has spread globally, there is a greater need to look for novel vaccines and drugs that alleviate and prevent contracting the virus. This includes identifying a possible lead bioactive compound that will block the coronavirus replication cycle to assist in the prevention and contamination of this current global pandemic.


  • 3D cell based analysis
  • Image-based screening for bioactive compounds for blocking SARS-CoV-2
  • Can be used to neutralize antibodies, monobodies, or peptides


  • Rapid
  • High dimensional characterization
  • Predictable
  • Complex
  • Accurate
Patent Information:
Contact For More Information:
Lewis Humphreys
Licensing Manager, Eller College of Mngmt & OTT
The University of Arizona
Lead Inventor(s):
Curtis Thorne
Elaheh Alizadeh
Koenraad Van Doorslaer
Samuel Campos
Carly Cabel
Shuaizhi Li